<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font3" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font4" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="9" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font6" size="9" family="Symbol" color="#000000"/>
	<fontspec id="font7" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font8" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font9" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font10" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font11" size="8" family="AkzidenzGroteskBE" color="#ffffff"/>
<text top="42" left="57" width="193" height="7" font="font0" id="p1_t1" reading_order_no="1" segment_no="0" tag_type="title">Breast Cancer Research Vol 7 No 6    Reis-Filho et al.<b>Breast Cancer Research</b></text>
<text top="735" left="18" width="23" height="8" font="font3" id="p1_t2" reading_order_no="0" segment_no="14" tag_type="text">R1031</text>
<text top="85" left="57" width="240" height="9" font="font4" id="p1_t3" reading_order_no="2" segment_no="1" tag_type="text">exhibited more than five signals per nuclei or large gene signal<i>et al.</i></text>
<text top="97" left="57" width="72" height="9" font="font4" id="p1_t4" reading_order_no="3" segment_no="1" tag_type="text">clusters [8,34,36].</text>
<text top="120" left="57" width="240" height="9" font="font4" id="p1_t5" reading_order_no="4" segment_no="3" tag_type="text">Out of the 112 cases of metaplastic breast carcinomas in our</text>
<text top="132" left="57" width="240" height="9" font="font4" id="p1_t6" reading_order_no="5" segment_no="3" tag_type="text">series, 25 had sufficient material in the blocks and were suc-<a href="">8</a>,<a href="">34,36]</a>.</text>
<text top="144" left="57" width="240" height="9" font="font4" id="p1_t7" reading_order_no="6" segment_no="3" tag_type="text">cessfully analyzed by both immunohistochemistry and CISH</text>
<text top="156" left="57" width="83" height="9" font="font4" id="p1_t8" reading_order_no="7" segment_no="3" tag_type="text">for EGFR and HER2.</text>
<text top="179" left="57" width="204" height="8" font="font5" id="p1_t9" reading_order_no="8" segment_no="4" tag_type="title">Correlation between EGFR overexpression and</text>
<text top="191" left="57" width="231" height="8" font="font5" id="p1_t10" reading_order_no="9" segment_no="4" tag_type="title">amplification and clinicopathological parameters and</text>
<text top="203" left="57" width="33" height="8" font="font5" id="p1_t11" reading_order_no="10" segment_no="4" tag_type="title">survival<b>Correlation between EGFR overexpression and </b></text>
<text top="214" left="57" width="240" height="9" font="font4" id="p1_t12" reading_order_no="11" segment_no="5" tag_type="text">Follow-up information was available for 23 out of 25 patients,<b>amplification and clinicopathological parameters and </b></text>
<text top="226" left="57" width="241" height="9" font="font4" id="p1_t13" reading_order_no="12" segment_no="5" tag_type="text">with follow-up periods ranging from 5.5 to 124.3 months<b>survival</b></text>
<text top="238" left="57" width="240" height="9" font="font4" id="p1_t14" reading_order_no="13" segment_no="5" tag_type="text">(median 34.6 months, mean 51.9 months). The Statview soft-</text>
<text top="250" left="57" width="240" height="9" font="font4" id="p1_t15" reading_order_no="14" segment_no="5" tag_type="text">ware package was used for all calculations. Correlations</text>
<text top="259" left="57" width="241" height="12" font="font4" id="p1_t16" reading_order_no="15" segment_no="5" tag_type="text">between categorical variables were performed using the χ 2</text>
<text top="273" left="57" width="240" height="9" font="font4" id="p1_t17" reading_order_no="16" segment_no="5" tag_type="text">test and Fisher's exact test. Correlations between continuous</text>
<text top="285" left="57" width="240" height="9" font="font4" id="p1_t18" reading_order_no="17" segment_no="5" tag_type="text">and categorical variables were performed with analysis of var-</text>
<text top="297" left="57" width="240" height="9" font="font4" id="p1_t19" reading_order_no="18" segment_no="5" tag_type="text">iance. DFS and OS were expressed as the number of months</text>
<text top="308" left="57" width="240" height="9" font="font4" id="p1_t20" reading_order_no="19" segment_no="5" tag_type="text">from diagnosis to the occurrence of an event (local recur-</text>
<text top="320" left="57" width="240" height="9" font="font4" id="p1_t21" reading_order_no="20" segment_no="5" tag_type="text">rence/metastasis and disease-related death, respectively).</text>
<text top="332" left="57" width="240" height="9" font="font4" id="p1_t22" reading_order_no="21" segment_no="5" tag_type="text">Cumulative survival probabilities were calculated using the</text>
<text top="344" left="57" width="240" height="9" font="font4" id="p1_t23" reading_order_no="22" segment_no="5" tag_type="text">Kaplan–Meier method. Differences between survival rates</text>
<text top="355" left="57" width="240" height="9" font="font4" id="p1_t24" reading_order_no="23" segment_no="5" tag_type="text">were tested using the log-rank test. All tests were two-tailed,</text>
<text top="367" left="57" width="133" height="9" font="font4" id="p1_t25" reading_order_no="24" segment_no="5" tag_type="text">with a confidence interval of 95%.</text>
<text top="390" left="57" width="39" height="10" font="font8" id="p1_t26" reading_order_no="25" segment_no="6" tag_type="title">Results</text>
<text top="402" left="57" width="240" height="9" font="font4" id="p1_t27" reading_order_no="26" segment_no="8" tag_type="text">Table 1 summarizes the results of the histological, immunohis-</text>
<text top="414" left="57" width="240" height="9" font="font4" id="p1_t28" reading_order_no="27" segment_no="8" tag_type="text">tochemical and CISH analyses. Briefly, 19 out of 25 (76%)</text>
<text top="426" left="57" width="240" height="9" font="font4" id="p1_t29" reading_order_no="28" segment_no="8" tag_type="text">cases exhibited EGFR positivity of grade 3+. No samples</text>
<text top="438" left="57" width="240" height="9" font="font4" id="p1_t30" reading_order_no="29" segment_no="8" tag_type="text">showed EGFR grade 2+ positivity, whereas four cases were<b>Results</b></text>
<text top="449" left="57" width="240" height="9" font="font4" id="p1_t31" reading_order_no="30" segment_no="8" tag_type="text">EGFR 1+. Out of the 19 cases with EGFR grade 3+ expres-<a href="">Table 1 su</a>mmarizes the results of the histological, immunohis-</text>
<text top="461" left="57" width="241" height="9" font="font4" id="p1_t32" reading_order_no="31" segment_no="8" tag_type="text">sion, seven (37%) exhibited EGFR gene amplification (Fig. 1).</text>
<text top="473" left="57" width="240" height="9" font="font4" id="p1_t33" reading_order_no="32" segment_no="8" tag_type="text">Three out of nine carcinomas with squamous metaplasia and</text>
<text top="485" left="57" width="240" height="9" font="font4" id="p1_t34" reading_order_no="33" segment_no="8" tag_type="text">four out of 10 spindle cell carcinomas had EGFR amplification,</text>
<text top="496" left="57" width="240" height="9" font="font4" id="p1_t35" reading_order_no="34" segment_no="8" tag_type="text">whereas no matrix producing breast carcinomas showed any</text>
<text top="508" left="57" width="240" height="9" font="font4" id="p1_t36" reading_order_no="35" segment_no="8" tag_type="text">amplification. Interestingly, similar numbers of EGFR signals</text>
<text top="520" left="57" width="240" height="9" font="font4" id="p1_t37" reading_order_no="36" segment_no="8" tag_type="text">were observed in the epithelial and in the metaplastic ele-<i>EGFR</i></text>
<text top="532" left="57" width="240" height="9" font="font4" id="p1_t38" reading_order_no="37" segment_no="8" tag_type="text">ments. One case exhibited HER2 grade 2+ positivity with Her-<a href="">1).</a></text>
<text top="543" left="57" width="241" height="9" font="font4" id="p1_t39" reading_order_no="38" segment_no="8" tag_type="text">ceptest ® , but HER2 gene amplification was not observed (Fig.</text>
<text top="555" left="57" width="10" height="9" font="font4" id="p1_t40" reading_order_no="39" segment_no="8" tag_type="text">2).</text>
<text top="579" left="57" width="240" height="9" font="font4" id="p1_t41" reading_order_no="40" segment_no="10" tag_type="text">No association between EGFR overexpression or amplifica-<i>EGFR</i></text>
<text top="590" left="57" width="240" height="9" font="font4" id="p1_t42" reading_order_no="41" segment_no="10" tag_type="text">tion and clinicopathological features was observed (Table 2).</text>
<text top="602" left="57" width="240" height="9" font="font4" id="p1_t43" reading_order_no="42" segment_no="10" tag_type="text">EGFR overexpression showed no association with DFS or</text>
<text top="614" left="57" width="240" height="9" font="font4" id="p1_t44" reading_order_no="43" segment_no="10" tag_type="text">OS. Patients with tumours harbouring EGFR amplification had</text>
<text top="626" left="57" width="173" height="9" font="font4" id="p1_t45" reading_order_no="44" segment_no="10" tag_type="text">a trend toward shorter DFS and OS (Fig. 3).<i>EGFR</i></text>
<text top="649" left="57" width="57" height="10" font="font8" id="p1_t46" reading_order_no="45" segment_no="12" tag_type="title">Discussion</text>
<text top="661" left="57" width="240" height="9" font="font4" id="p1_t47" reading_order_no="46" segment_no="13" tag_type="text">In recent studies, we and others demonstrated that MBCs fre-</text>
<text top="673" left="57" width="240" height="9" font="font4" id="p1_t48" reading_order_no="47" segment_no="13" tag_type="text">quently overexpress EGFR and lack HER2 overexpression. In</text>
<text top="684" left="57" width="240" height="9" font="font4" id="p1_t49" reading_order_no="48" segment_no="13" tag_type="text">a previous study [26] we demonstrated that up to 83% of all</text>
<text top="696" left="57" width="240" height="9" font="font4" id="p1_t50" reading_order_no="49" segment_no="13" tag_type="text">MBCs show EGFR overexpression. Leibl and Moinfar [12]</text>
<text top="708" left="57" width="240" height="9" font="font4" id="p1_t51" reading_order_no="50" segment_no="13" tag_type="text">described positivity for EGFR in 70% of MBCs, but those</text>
<text top="720" left="57" width="240" height="9" font="font4" id="p1_t52" reading_order_no="51" segment_no="13" tag_type="text">authors also considered cases with grade 1+ expression to be<i>HER2</i></text>
<text top="532" left="315" width="240" height="9" font="font4" id="p1_t53" reading_order_no="66" segment_no="9" tag_type="text">positive. When only grade 2+ and 3+ expression was consid-</text>
<text top="543" left="315" width="241" height="9" font="font4" id="p1_t54" reading_order_no="67" segment_no="9" tag_type="text">ered to represent positivity, 60% (12/20) were positive. In the<a href="">2).</a></text>
<text top="555" left="315" width="240" height="9" font="font4" id="p1_t55" reading_order_no="68" segment_no="9" tag_type="text">present study we demonstrated that 76% (19/25) of MBCs</text>
<text top="567" left="315" width="240" height="9" font="font4" id="p1_t56" reading_order_no="69" segment_no="9" tag_type="text">overexpressed EGFR. The differences between our findings<a href="">able 2).</a></text>
<text top="579" left="315" width="240" height="9" font="font4" id="p1_t57" reading_order_no="70" segment_no="9" tag_type="text">and those of Leibl and Moinfar [12] may be related to the dif-</text>
<text top="590" left="315" width="240" height="9" font="font4" id="p1_t58" reading_order_no="71" segment_no="9" tag_type="text">ferent antibody clones used and different antigen retrieval</text>
<text top="602" left="315" width="36" height="9" font="font4" id="p1_t59" reading_order_no="72" segment_no="9" tag_type="text">methods.<a href="">shorter DFS and OS (Fig. 3).</a></text>
<text top="626" left="315" width="240" height="9" font="font4" id="p1_t60" reading_order_no="73" segment_no="11" tag_type="text">The mechanism underlying EGFR overexpression has not<b>Discussion</b></text>
<text top="637" left="315" width="240" height="9" font="font4" id="p1_t61" reading_order_no="74" segment_no="11" tag_type="text">been investigated in MBCs. In the present study we demon-</text>
<text top="649" left="315" width="241" height="9" font="font4" id="p1_t62" reading_order_no="75" segment_no="11" tag_type="text">strated that EGFR is amplified in 28% (7/25) of MBCs and in</text>
<text top="661" left="315" width="241" height="9" font="font4" id="p1_t63" reading_order_no="76" segment_no="11" tag_type="text">37% (7/19) of MBCs with EGFR overexpression. Although<a href="">study [26] we demon</a>strated that up to 83% of all</text>
<text top="673" left="315" width="240" height="9" font="font4" id="p1_t64" reading_order_no="77" segment_no="11" tag_type="text">only six cases with heterologous elements (four matrix produc-<a href="">ibl and Moinfar [12]</a></text>
<text top="684" left="315" width="240" height="9" font="font4" id="p1_t65" reading_order_no="78" segment_no="11" tag_type="text">ing carcinomas and two carcinomas with heterologous ele-</text>
<text top="696" left="315" width="240" height="9" font="font4" id="p1_t66" reading_order_no="79" segment_no="11" tag_type="text">ments) were analyxed, no amplification was found in these two</text>
<text top="708" left="315" width="240" height="9" font="font4" id="p1_t67" reading_order_no="80" segment_no="11" tag_type="text">subtypes of MBC. Identification of areas of squamous differen-</text>
<text top="720" left="315" width="240" height="9" font="font4" id="p1_t68" reading_order_no="81" segment_no="11" tag_type="text">tiation in spindle cell carcinomas and the presence of spindle</text>
<text top="85" left="315" width="31" height="7" font="font10" id="p1_t69" reading_order_no="52" segment_no="2" tag_type="title">Figure 1</text>
<text top="399" left="315" width="185" height="7" font="font11" id="p1_t70" reading_order_no="53" segment_no="7" tag_type="text">EGFR overexpression and gene amplification in MBCs</text>
<text top="399" left="315" width="230" height="7" font="font1" id="p1_t71" reading_order_no="54" segment_no="7" tag_type="text">EGFR overexpression and gene amplification in MBCs. Photomicro-<a href="">12] may be related to </a>the dif-</text>
<text top="408" left="315" width="241" height="7" font="font1" id="p1_t72" reading_order_no="55" segment_no="7" tag_type="text">graphs of (a) a spindle cell metaplastic breast carcinoma (haematoxylin</text>
<text top="418" left="315" width="233" height="7" font="font1" id="p1_t73" reading_order_no="56" segment_no="7" tag_type="text">and eosin) showing (b) grade 3+ immunohistochemical positivity for</text>
<text top="427" left="315" width="219" height="7" font="font1" id="p1_t74" reading_order_no="57" segment_no="7" tag_type="text">EGFR and (c) EGFR gene amplification (&gt;5 signals per nucleus</text>
<text top="437" left="315" width="241" height="7" font="font1" id="p1_t75" reading_order_no="58" segment_no="7" tag_type="text">[CISH]). Inset in panel c: note the bizarre neoplastic cell with more than</text>
<text top="446" left="315" width="237" height="7" font="font1" id="p1_t76" reading_order_no="59" segment_no="7" tag_type="text">10 copies of EGFR . (d) Breast carcinoma with squamous metaplasia</text>
<text top="456" left="315" width="237" height="7" font="font1" id="p1_t77" reading_order_no="60" segment_no="7" tag_type="text">(haematoxylin and eosin) with (e) EGFR grade 3+ immunohistochemi-<i>EGFR</i></text>
<text top="465" left="315" width="236" height="7" font="font1" id="p1_t78" reading_order_no="61" segment_no="7" tag_type="text">cal positivity. (f) CISH demonstrating EGFR amplification (clusters of</text>
<text top="475" left="315" width="234" height="7" font="font1" id="p1_t79" reading_order_no="62" segment_no="7" tag_type="text">signals in the nuclei of neoplastic cells). Note the presence of one or</text>
<text top="484" left="315" width="241" height="7" font="font1" id="p1_t80" reading_order_no="63" segment_no="7" tag_type="text">two signals in the nuclei of stromal cells (arrowheads). CISH, chromog-</text>
<text top="494" left="315" width="228" height="7" font="font1" id="p1_t81" reading_order_no="64" segment_no="7" tag_type="text">enic in situ hybridization; EGFR, epidermal growth factor receptor;</text>
<text top="503" left="315" width="123" height="7" font="font1" id="p1_t82" reading_order_no="65" segment_no="7" tag_type="text">MBC, metaplastic breast carcinoma.</text>
</page>
</pdf2xml>
